Financials and Corporate

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), announces that it will host an event for analysts and investors in London to discuss the Company’s corporate strategy and ongoing...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on June 2, 2016, in Marseille, France. All...

Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...

Cash, cash equivalents and financial instruments of the Company amounted to €255.8 million ; Broad innovative pipeline including three clinical-stage programs; expect first clinical data in 2016; Two...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the second quarter of 2016: Gilbert Dupont...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 2, 2016, at 10:00 am in its headquarters, 117 avenue de Luminy...

Cash, cash equivalents and financial instruments amounting to €274 million*; Landmark co-development and commercialization agreement with AstraZeneca for monalizumab in immuno-oncology; Building...